OGEN Stock — Oragenics Inc.: Cash, EV, Pipeline

Share price

$0.48

Market cap

$2.2M

Cash

$3.9M

Enterprise value

-$1.7M

Balance sheet

Cash	$3.9M
Debt	$0.0M
Net cash	$3.9M
Enterprise value	-$1.7M
Basic shares	4.5M shares
Fully diluted shares	17.4M shares
Fully diluted market cap	$8.3M
Cash per share	$0.86

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OGEN daily closes…

Loading price history…

Pipeline assets

ONP-002

Phase 2 · Active Modality: small molecule

Indications

Mild traumatic brain injury (mTBI) (Phase 2)

Status note Lead product candidate; synthetic neurosteroid formulation for mTBI, delivered via intranasal device. Completed a Phase 1 clinical trial in healthy human subjects; company conducting Phase 2 work and nonclinical studies.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Neurosteroid enantiomer
Lead indication	Mild Traumatic Brain Injury, Concussion
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06870240	Phase 2	Not yet recruiting	Sponsor	OGEN	—	Mild Traumatic Brain Injury, Concussion	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Oragenics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

OGEN — Oragenics Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials